SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    E Cariani, L Roli, G Missale, E Villa, C Ferrari, T Trenti, Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis, The Pharmacogenomics Journal, 2015,

    CrossRef

  2. 2
    Wael Abdel-Razek, Imam Waked, Optimal therapy in genotype 4 chronic hepatitis C: finally cured?, Liver International, 2015, 35,
  3. 3
    Qin Wu, Feng Yu Zhan, En Qiang Chen, Cong Wang, Zhen Zhen Li, Xue Zhong Lei, Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China, Hepatitis Monthly, 2015, 15, 6

    CrossRef

  4. 4
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2014, 60, 2, 392

    CrossRef

  5. 5
    Srunthron Akkarathamrongsin, Vo Duy Thong, Sunchai Payungporn, Kittiyod Poovorawan, Phisit Prapunwattana, Yong Poovorawan, Pisit Tangkijvanich, IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6, Journal of Medical Virology, 2014, 86, 9
  6. 6
    Samar Samir Youssef, Eman Abd El- Razek Abbas, Asmaa Mostafa Abd el Aal, Moataza Hassan Omran, Ahmed Barakat, Sameh Mohamed Seif, IL28Brs 12979860 Predicts Response to Treatment in Egyptian Hepatitis C Virus Genotype 4 Patients and Alpha Fetoprotein Increases Its Predictive Strength, Journal of Interferon & Cytokine Research, 2014, 34, 7, 505

    CrossRef

  7. 7
    Satoshi Shakado, Shotaro Sakisaka, Takeshi Okanoue, Kazuaki Chayama, Namiki Izumi, Joji Toyoda, Eiji Tanaka, Akio Ido, Tetsuo Takehara, Kentaro Yoshioka, Yoichi Hiasa, Hideyuki Nomura, Masataka Seike, Yoshiyuki Ueno, Hiromitsu Kumada, Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan, Hepatology Research, 2014, 44, 9
  8. 8
    Heba M. Gouda, Zainab A. El-Saadany, Neveen B. Foad, Rabab M. Salama, Interleukin 28B Polymorphisms and Therapy Response in Egyptian Hepatitis C Genotype-4 Patients, DNA and Cell Biology, 2014, 33, 9, 642

    CrossRef

  9. 9
    Brittany E. Yee, Nghia H. Nguyen, Bing Zhang, Philip Vutien, Carrie R. Wong, Glen A. Lutchman, Mindie H. Nguyen, Meta-analysis, European Journal of Gastroenterology & Hepatology, 2014, 26, 11, 1189

    CrossRef

  10. 10
    Wael Abdel-Razek, Imam Waked, Optimal Management of HCV Genotype 4, Current Hepatology Reports, 2014, 13, 4, 286

    CrossRef

  11. 11
    Abd Elrazek Abd Elrazek, Shymaa E. Bilasy, Abduh E. M. Elbanna, Abd Elhalim A. Elsherif, Prior to the Oral Therapy, What Do We Know About HCV-4 in Egypt, Medicine, 2014, 93, 28, e204

    CrossRef

  12. 12
    Amira Youssef Shaala, Mona Gamal Morsi, Reem Abdel Hameed Harfoush, Ehab Hassan ElKhouly, Mohamed Abdel Rahman Ahmed, Mohamed Nabil Roshdy, Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis, Alexandria Journal of Medicine, 2014,

    CrossRef

  13. 13
    Imam Waked, Waheed Doss, Manal Hamdy El-Sayed, Chris Estes, Homie Razavi, Gamal Shiha, Ayman Yosry, Gamal Esmat, The current and future disease burden of chronic hepatitis C virus infection in Egypt, Arab Journal of Gastroenterology, 2014, 15, 2, 45

    CrossRef

  14. 14
    Hany Shehab, Tamer Elbaz, Dalia Deraz, Amal Hafez, Inas Elattar, The Efficacy of aHansenula-Derived 20 kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C, Journal of Interferon & Cytokine Research, 2014, 34, 9, 727

    CrossRef

  15. 15
    Marina Kawaguchi-Suzuki, Reginald F. Frye, The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014, 34, 2
  16. 16
    Rosa Quiles-Pérez, Esther José Pavón-Castillero, Paloma Muñoz-de-Rueda, Isabel Carmona, Javier Salmerón, Valor de la genética en la era de la terapia triple frente al virus de la hepatitis C, Gastroenterología y Hepatología, 2014, 37, 7, 427

    CrossRef

  17. 17
    C. Bucci, A. von Delft, A. Christian, V. M. Flemming, A. Harrison, J. Halliday, J. Collier, C. Manganis, P. Klenerman, W. Irving, E. Barnes, 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy, Journal of General Virology, 2013, 94, Pt_6, 1259

    CrossRef

  18. 18
    Haruki Komatsu, Ayano Inui, Tomoyuki Tsunoda, Tsuyoshi Sogo, Tomoo Fujisawa, Association between an IL-28B genetic polymorphism and the efficacy of the response-guided pegylated interferon therapy in children with chronic hepatic C infection, Hepatology Research, 2013, 43, 4
  19. 19
    Alessio Aghemo, Elisabetta Degasperi, Maria Grazia Rumi, Enrico Galmozzi, Luca Valenti, Raffaele De Francesco, Stella De Nicola, Cristina Cheroni, Eleonora Grassi, Massimo Colombo, Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients, BioMed Research International, 2013, 2013, 1

    CrossRef

  20. You have free access to this content20
    Eleonora Grassi, Alessio Aghemo, How to optimize HCV therapy in genotype 2 patients, Liver International, 2013, 33,
  21. 21
    N. Antaki, S. Bibert, K. Kebbewar, F. Asaad, O. Baroudi, S. Alideeb, M. Hadad, D. Abboud, H. Sabah, P.-Y. Bochud, F. Negro, IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4, Journal of Viral Hepatitis, 2013, 20, 1
  22. 22
    Ayman A. Abdo, Mohammed N. Al-Ahdal, Saira S. Khalid, Ahmed Helmy, Faisal M. Sanai, Khalid Alswat, Waleed Al-hamoudi, Safiyya M. Ali, Hamad I. Al-Ashgar, Abdallah Al-Mdani, Ali Albenmousa, Faleh Z. Al Faleh, Mashael Al-Anazi, Nisreen Khalaf, Ahmed Al-Qahtani, IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection, Hepatology International, 2013, 7, 2, 533

    CrossRef

  23. 23
    Andres Duarte-Rojo, Matthew G. Deneke, Michael R. Charlton, Interleukin-28B polymorphism in hepatitis C and liver transplantation, Liver Transplantation, 2013, 19, 1
  24. 24
    Fabio Salvatore Macaluso, Marcello Maida, Maria Giovanna Minissale, Teresa Li Vigni, Simona Attardo, Emanuele Orlando, Salvatore Petta, Metabolic Factors and Chronic Hepatitis C: A Complex Interplay, BioMed Research International, 2013, 2013, 1

    CrossRef

  25. 25
    Marwa Khairy, Rabab Fouad, Mahassen Mabrouk, Wafaa El-Akel, Abu Bakr Awad, Rabab Salama, Mayada Elnegouly, Olfat Shaker, The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis, Hepatitis Monthly, 2013, 13, 6

    CrossRef

  26. 26
    J. A. Holmes, P. V. Desmond, A. J. Thompson, Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?, Journal of Viral Hepatitis, 2012, 19, 10
  27. 27
    Alexander J. Thompson, Genetic Factors and Hepatitis C Virus Infection, Gastroenterology, 2012, 142, 6, 1335

    CrossRef

  28. 28
    Monika Rau, Katharina Baur, Andreas Geier, Host Genetic Variants in the Pathogenesis of Hepatitis C, Viruses, 2012, 4, 12, 3281

    CrossRef

  29. 29
    Christoph T. Berger, Arthur Y. Kim, IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment, Infectious Disease Clinics of North America, 2012, 26, 4, 863

    CrossRef

  30. 30
    L. Valenti, A. Aghemo, A. F. Stättermayer, P. Maggioni, S. Nicola, B. M. Motta, M. G. Rumi, P. Dongiovanni, P. Ferenci, M. Colombo, S. Fargion, Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin, Alimentary Pharmacology & Therapeutics, 2012, 35, 12
  31. 31
    Y. Chen, H.-X. Xu, L.-J. Wang, X.-X. Liu, R. I. Mahato, Y.-R. Zhao, Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin, Alimentary Pharmacology & Therapeutics, 2012, 36, 2
  32. 32
    David R Booth, Golo Ahlenstiel, Jacob George, Pharmacogenomics of hepatitis C infections: personalizing therapy, Genome Medicine, 2012, 4, 12, 99

    CrossRef

  33. 33
    Vasilios Papastergiou, Dimitrios Dimitroulopoulos, Lamprini Skorda, Philippos Lisgos, Ioannis Ketikoglou, Nikolaos Kostas, Stylianos Karatapanis, Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?, Journal of Medical Virology, 2012, 84, 8
  34. 34
    Emilie Estrabaud, Olivier Lada, Tarik Asselah, Reply to “Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C”, Journal of Hepatology, 2012, 57, 3, 706

    CrossRef

  35. 35
    Alessio Aghemo, Gian Maria Prati, Massimo Colombo, Reply to: “The “pegylated” story continues – Perhaps because both ends (α2a and α2b) are true?”, Journal of Hepatology, 2012, 57, 1, 229

    CrossRef